Zhitong Finance App News, Sihuan Biotech (000518.SZ) announced that the company plans to acquire 65.6146% of the shares of Zhongrun Pharmaceutical Co., Ltd. (“Zhongrun Pharmaceutical”, the “target company”) in cash at a transaction price of 160 million yuan. After the transaction is completed, Zhongrun Pharmaceutical will become the company's holding subsidiary. At the same time, the target company will target the targeted capital reduction party to reduce its total holdings of 17.9817% of the target company's shares (corresponding to the target company's unpaid capital contribution of 337.1575 million yuan), and will not pay compensation for the capital reduction. After the capital reduction is completed, the company will hold 80% of the shares in the target company.

Zhitong Finance App News, Sihuan Biotech (000518.SZ) announced that the company plans to acquire 65.6146% of the shares of Zhongrun Pharmaceutical Co., Ltd. (“Zhongrun Pharmaceutical”, the “target company”) in cash at a transaction price of 160 million yuan. After the transaction is completed, Zhongrun Pharmaceutical will become the company's holding subsidiary. At the same time, the target company will target the targeted capital reduction party to reduce its total holdings of 17.9817% of the target company's shares (corresponding to the target company's unpaid capital contribution of 337.1575 million yuan), and will not pay compensation for the capital reduction. After the capital reduction is completed, the company will hold 80% of the shares in the target company.